2026-06-14T03:39:14Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/183352024-11-28T14:55:10Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927
Repisalud
author
Pérez-Belmonte, Luis M.
author
Ricci, Michele
author
Sanz-Cánovas, Jaime
author
Cobos-Palacios, Lidia
author
López-Carmona, María D.
author
Ruiz-Moreno, M. Isabel
author
Millán-Gómez, Mercedes
author
Bernal-López, M. Rosa
author
Jansen-Chaparro, Sergio
author
Gómez-Huelgas, Ricardo
authoraffiliation
[Pérez-Belmonte,LM; Ricci,M; Sanz-Cánovas,J; Cobos-Palacios,L; López-Carmona,MD; Ruiz-Moreno,MI; Bernal-López,MR; Jansen-Chaparro,S; Gómez-Huelgas,R] Servicio de Medicina Interna, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga (UMA), Málaga, Spain. [Pérez-Belmonte,LM] Servicio de Medicina Interna, Hospital Helicópteros Sanitarios, Marbella, Spain. [Pérez-Belmonte,LM; Millán-Gómez,M] Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain. [Bernal-López,MR; Gómez-Huelgas,R] Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III, Madrid, Spain.
2024-02-19T15:28:10Z
2024-02-19T15:28:10Z
2021-05-08
10.3390/jcm10092013
2077-0383
Journal of Clinical Medicine
http://hdl.handle.net/10668/4533
34066707
http://hdl.handle.net/20.500.12105/18335
Canagliflozin is a sodium-glucose co-transporter 2 inhibitor that reduces glycemia as well as the risk of cardiovascular events. Our main objective was to analyze antidiabetic treatment de-intensification and the glycemic efficacy of replacing antidiabetic agents (excluding metformin) with canagliflozin in patients with heart failure and type 2 diabetes with poor glycemic control. In this observational, retrospective, real-world study, we selected patients treated with metformin in combination with ≥2 non-insulin antidiabetic agents or metformin in combination with basal insulin plus ≥1 non-insulin antidiabetic agent. Non-insulin antidiabetic agents were replaced with canagliflozin. Patients were followed-up on at three, six, and 12 months after the switch and a wide range of clinical variables were recorded. A total of 121 patients were included. From baseline to 12 months, the number of antidiabetic agents (3.1 ± 1.0 vs. 2.1 ± 0.8, p < 0.05), basal insulin dose (20.1 ± 9.8 vs. 10.1 ± 6.5 units, p < 0.01), and percentage of patients who used basal insulin (47.9% vs. 31.3%, p < 0.01) decreased. The proportion of patients who used diuretics also declined significantly. In addition, we observed improvement in glycemic control, with an increase in the proportion of patients with glycated hemoglobin <7% from 16.8% at three months to 63.5% at 12 (p < 0.001). Canagliflozin use was also beneficial in terms of body weight, blood pressure, heart failure status, functional class, and cardiovascular-renal risk. There were also reductions in the number of emergency department visits and hospitalizations for heart failure. Moreover, canagliflozin was well-tolerated, with a low rate of drug-related discontinuation. Mounting evidence from randomized controlled trials and real-world studies point to the beneficial profile of sodium-glucose co-transporter type 2 inhibitors such as canagliflozin in patients with heart failure.
eng
De-intensification
Efficacy
Canagliflozin
Heart failure
Type 2 diabetes
Capacidad de respuesta
Eficacia
Canagliflozina
Insuficiencia cardíaca
Diabetes mellitus tipo 2
Hipoglucemiantes
De-Intensification of Antidiabetic Treatment Using Canagliflozin in Patients with Heart Failure and Type 2 Diabetes: Cana-Switch-HF Study
research article